Next Article in Journal
Impact of Malocclusion, Tooth Loss and Oral Hygiene Habits on Quality of Life in Orthodontic Patients: A Cross-Sectional Study
Previous Article in Journal
Assessment of Referrals and Hospitalizations in the Hospital Transformed into COVID-19 Facility in Poland during the “Spring Wave” of the Epidemic in 2020—A Cross-Sectional Study
Previous Article in Special Issue
Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian Settings
Article

Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study

1
Liver Unit, Fondazione “Casa Sollievo Della Sofferenza” IRCCS, 71013 San Giovanni Rotondo, Italy
2
Department of Oncology and Onco-Hematology, University of Milan, 20122 Milan, Italy
3
Hepatology and Liver Transplantation Unit, Azienda Ospedaliero Universitaria, 33100 Udine, Italy
4
Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, 28100 Novara, Italy
5
Department of Mental Health and Public Medicine–Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 81100 Caserta, Italy
6
Department of Medical Sciences, University of Turin, 10124 Turin, Italy
7
Gilead Sciences, Medical Affairs Italy, 202124 Milan, Italy
8
Gilead Sciences, Global Medical Affairs, Stockley Park, London UB11 1BD, UK
9
CliCon S.r.l. Health, Economics & Outcomes Research, 40137 Bologna, Italy
10
Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Matteo Franchi, Anna Cantarutti and Federico Rea
Int. J. Environ. Res. Public Health 2021, 18(13), 7144; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18137144
Received: 10 May 2021 / Revised: 25 June 2021 / Accepted: 25 June 2021 / Published: 3 July 2021
(This article belongs to the Special Issue Real-World Evidence in Clinical Epidemiology and Public Health)
This Italian observational real-world study aims to assess in chronic hepatitis C virus (HCV) patients treated with pangenotypic direct acting agents (pDAAs) glecaprevir/pibrentasvir (GLE/PIB) or sofosbuvir/velpatasvir (SOF/VEL) the potential drug–drug interactions (DDIs) with concomitant medications prescribed, with a focus on cardiovascular and system nervous (CNS) co-medications. Data were collected from administrative databases covering 6.9 million health-assisted individuals. All patients prescribed SOF/VEL or GLE/PIB between 11/2017 and 12/2018 were included. Patients were analyzed while on DAA. DDIs were identified according to the Liverpool University tool. Overall, 3181 HCV patients were included: 1619 in the GLE/PIB cohort and 1562 in the SOF/VEL cohort. SOF/VEL patients were generally older than GLE/PIB ones (mean age 58.4 vs. 53.1, p < 0.001) and had more cardiovascular and CNS comorbidities (58% vs. 42%, p < 0.001 and 33% vs. 28%, p = 0.002, respectively). Contraindications due to DDIs in the GLE/PIB cohort affected 9.3% and 3.2% of patients before and on DAA, respectively, while the percentages in the SOF/VEL cohort were 3.2% before and 0.4% after pDAAs initiation. Among GLE/PIB patients, 2.7% had cardiovascular drugs (all statins) contraindicated while on DAA. The potential DDIs between cardiovascular drugs and SOF/VEL were mainly with statins (5%). SOF/VEL was prescribed in patients with older age and with more cardiovascular and CNS comorbidities. Despite this, a proportion of contraindicated drugs lower than that of GLE/PIB was registered. View Full-Text
Keywords: drug–drug interactions; glecaprevir/pibrentasvir; HCV; sofosbuvir/velpatasvir drug–drug interactions; glecaprevir/pibrentasvir; HCV; sofosbuvir/velpatasvir
Show Figures

Figure 1

MDPI and ACS Style

Mangia, A.; Scaglione, F.; Toniutto, P.; Pirisi, M.; Coppola, N.; Di Perri, G.; Alvarez Nieto, G.; Calabrese, S.; Hernandez, C.; Perrone, V.; Degli Esposti, L.; Fagiuoli, S., on the behalf of a LHUs Study Group. Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int. J. Environ. Res. Public Health 2021, 18, 7144. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18137144

AMA Style

Mangia A, Scaglione F, Toniutto P, Pirisi M, Coppola N, Di Perri G, Alvarez Nieto G, Calabrese S, Hernandez C, Perrone V, Degli Esposti L, Fagiuoli S on the behalf of a LHUs Study Group. Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. International Journal of Environmental Research and Public Health. 2021; 18(13):7144. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18137144

Chicago/Turabian Style

Mangia, Alessandra, Francesco Scaglione, Pierluigi Toniutto, Mario Pirisi, Nicola Coppola, Giovanni Di Perri, Gema Alvarez Nieto, Stefano Calabrese, Candido Hernandez, Valentina Perrone, Luca Degli Esposti, and Stefano Fagiuoli on the behalf of a LHUs Study Group. 2021. "Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study" International Journal of Environmental Research and Public Health 18, no. 13: 7144. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18137144

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop